ELKRIDGE, Md. - Marylandian -- NEXS BioMedica Corporation, a leader in pharmaceutical innovation, is calling for urgent reforms to accelerate the development and approval of drugs targeting obesity, a chronic illness affecting over 40% of U.S. adults. The company emphasizes the need for streamlined regulatory pathways to address the growing public health and economic impact of obesity-related diseases.

"Obesity is a complex, chronic condition driving a host of life-threatening illnesses, yet it remains underrecognized and undertreated," said Dr. Marc Nelson, MD, Founder and Chairman of NEXS BioMedica. "Regulatory barriers hinder the timely delivery of innovative therapies to patients who desperately need them."

Repurposing Existing Drugs for Rapid Impact
NEXS BioMedica advocates for repurposing existing drugs with established safety profiles to expedite the creation of effective obesity treatments. Combining proven compounds with advanced delivery technologies, such as slow-release formulations, can reduce development timelines and enhance patient outcomes.

"Repurposing drugs is an underutilized strategy that could deliver solutions faster while ensuring safety and efficacy," Dr. Nelson added.

More on Marylandian

• U.S. Navy Returns to BEYA STEM Conference, Strengthening 40-Year Legacy of Military Recruitment and STEM Equity
• Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
• Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
• Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
• Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence

Addressing Regulatory Barriers
The company identifies several challenges that impede progress:

• Lengthy and expensive clinical trial requirements for chronic conditions.
• Limited expedited pathways for combination therapies or repurposed drugs.
• Insufficient recognition of obesity as a chronic illness requiring long-term treatment.

NEXS BioMedica urges agencies like the FDA to expand fast-track programs and prioritize research funding for obesity therapies. By reducing unnecessary delays, these reforms could save lives and reduce the $173 billion annual economic burden of obesity-related healthcare costs.

Collaborating for a Healthier Future
The company also calls for greater collaboration among pharmaceutical firms, healthcare providers, insurers, and policymakers to accelerate innovation and improve patient access to life-changing treatments.

"Addressing obesity as a chronic disease is a medical and economic imperative," said Dr. Nelson. "Streamlining drug development pathways is essential to curbing this epidemic."

About NEXS BioMedica Corporation
NEXS BioMedica is a pharmaceutical and biotechnology company pioneering therapies for weight management, chronic diseases, and metabolic disorders. Under Dr. Marc Nelson's leadership, the company leverages advanced technology to deliver transformative healthcare solutions.

Media Contact:
NEXS BioMedica Corporation
+1-571-580-2911 | media@nexsbiomedica.com | https://www.nexsbiomedica.com